TT-16 is under clinical development by Tessa Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TT-16’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TT-16 is under development for the treatment of HER2 positive solid tumors including head and neck squamous cell carcinoma, cancer of the salivary glands, lung cancer, breast cancer, bladder cancer, gastric cancer, esophageal cancer, colorectal cancer and pancreatic adenocarcinoma. The therapeutic candidate is a combination of adeno oncolytic virus (CAdVEC) and HER-2 CAR virus-specific T cells (HER2-CAR VSTs). It is administered intratumorally. It is developed based on VST technology. It was also under development for the treatment of liver cancer.
Tessa Therapeutics overview
Tessa Therapeutics is a clinical-stage biotechnology company that discovers, develops, and commercializes cancer immunotherapies that redirect the body’s powerful anti-viral immune response and identify and exterminate cancer cells. The company provides products for cancers including gastric carcinoma, cervical, nasopharyngeal, head, oropharyngeal, and neck cancer. It harnesses virus-specific T cell (VST) technology for the treatment of solid tumors. Tessa Therapeutics is also extending its VST platform and treat an array of solid tumors through combinatorial approaches with chimeric antigen receptors, antibodies, and oncolytic virus technologies. The company works in partnership with National Cancer Centre, Singapore, Baylor College of Medicine, and Agency for Science, Technology and Research. Tessa Therapeutics is headquartered in Singapore.
For a complete picture of TT-16’s drug-specific PTSR and LoA scores, buy the report here.